FDA Approves Moderna Flu Shot

The FDA approved Moderna’s mFlusiva, the first U.S. seasonal influenza vaccine made with mRNA technology, for adults ages 50 and older. The decision gives full approval for ages 50 to 64 and accelerated approval for adults 65 and older, with Moderna required to run an additional clinical trial in the older group. In a late-stage trial, mFlusiva was about 27% more effective than a standard flu shot, and Moderna expects it to be available for the 2026-2027 flu season.